Mark C. McKenna, Chairman, President & CEO at Prometheus Biosciences, Inc. (RXDX), sold 11,320 shares at $125.26 ($1.4M) on 2023-03-01, disclosed to the SEC on 2023-03-03.
Scheduled sale ($1.4M) by Chairman, President & CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $125.26 | 700 | $88K | 6.2% |
| 2 | $125.13 | 10,620 | $1.3M | 93.8% |
| Total | $125.14 avg | 11,320 | $1.4M | 100% |
| Filing → |
| RXDX | SELL | 2023-02-17 | $7.7M | — | Filing → |
| RXDX | SELL | 2023-01-19 | $3.0M | — | Filing → |
| BHC | SELL | 2019-08-21 | $470K | — | Filing → |